Fig. 4. Somatic mutations in ovarian and endometrial cancers according to clinical benefit.

a, TMB, MSIsensor score, mutational signatures and recurrent non-synonymous somatic mutations identified by whole-exome sequencing in endometrial cancers with clinical benefit (PFS ≥ 24 weeks) and without clinical benefit (PFS < 24 weeks). Cases are represented by columns and genes by rows. Only pathogenic mutations are shown. MSI status, dominant mutational signature, histologic types and mutation types are color-coded according to the legend. Percentages in bold indicate statistically significantly different. *P < 0.05, two-sided Fisherʼs exact test. First, dominant mutational signature; Second, secondary mutational signature. b, Association of CB (defined by PFS24) with TMB. c, Association of type of dMMR (genetic versus epigenetic) with CB (n = 32; one patient had no information available). d,e, Association of mutations in MEGF8 and SETD1B with CB (n = 33). Figure 4b: measure of center represents the median, with error bars representing 95% CI. Two-sided P value by Mann–Whitney test is shown. Figure 4c–e: chi-square statistical comparisons are shown, two-sided P value. No multiple comparison adjustment was used for any of the indicated analyses. CB, clinical benefit; NB, no benefit.